<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Public Health</journal-id>
<journal-title>Frontiers in Public Health</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Public Health</abbrev-journal-title>
<issn pub-type="epub">2296-2565</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpubh.2024.1384512</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Public Health</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Dynamics and features of transmission clusters of HIV-1 subtypes in the state of S&#x00E3;o Paulo, Brazil</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Pimentel</surname> <given-names>Victor</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1636166/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Pineda-Pe&#x00F1;a</surname> <given-names>Andrea</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Sebasti&#x00E3;o</surname> <given-names>Cruz S.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>de Paula</surname> <given-names>Jo&#x00E3;o L.</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ahagon</surname> <given-names>Cintia M.</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Pingarilho</surname> <given-names>Marta</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/692192/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Martins</surname> <given-names>M. Ros&#x00E1;rio O.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Coelho</surname> <given-names>Luana P. O.</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Matsuda</surname> <given-names>Elaine M.</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2714403/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Alves</surname> <given-names>Daniela</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Abecasis</surname> <given-names>Ana B.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn0006"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/652473/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Br&#x00ED;gido</surname> <given-names>Lu&#x00ED;s F. M.</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="author-notes" rid="fn0006"><sup>&#x2020;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Global Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation Towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical (IHMT), Universidade NOVA de Lisboa (UNL)</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff>
<aff id="aff2"><sup>2</sup><institution>Centro de Investiga&#x00E7;&#x00E3;o em Sa&#x00FA;de de Angola (CISA)</institution>, <addr-line>Caxito</addr-line>, <country>Angola</country></aff>
<aff id="aff3"><sup>3</sup><institution>Instituto Nacional de Investiga&#x00E7;&#x00E3;o em Sa&#x00FA;de (INIS)</institution>, <addr-line>Luanda</addr-line>, <country>Angola</country></aff>
<aff id="aff4"><sup>4</sup><institution>Instituto Adolfo Lutz</institution>, <addr-line>S&#x00E3;o Paulo</addr-line>, <country>Brazil</country></aff>
<aff id="aff5"><sup>5</sup><institution>Secretaria da Sa&#x00FA;de de Santo Andr&#x00E9;</institution>, <addr-line>S&#x00E3;o Paulo</addr-line>, <country>Brazil</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0007">
<p>Edited by: Samantha Wisely, University of Florida, United States</p>
</fn>
<fn fn-type="edited-by" id="fn0008">
<p>Reviewed by: Adetayo Emmanuel Obasa, Stellenbosch University, South Africa</p>
<p>Ibrar Ahmed, Alpha Genomics Private Limited, Pakistan</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Victor Pimentel, <email>victor.pimentel@ihmt.unl.pt</email></corresp>
<fn fn-type="equal" id="fn0006">
<p><sup>&#x2020;</sup>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>12</volume>
<elocation-id>1384512</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>02</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Pimentel, Pineda-Pe&#x00F1;a, Sebasti&#x00E3;o, de Paula, Ahagon, Pingarilho, Martins, Coelho, Matsuda, Alves, Abecasis and Br&#x00ED;gido.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Pimentel, Pineda-Pe&#x00F1;a, Sebasti&#x00E3;o, de Paula, Ahagon, Pingarilho, Martins, Coelho, Matsuda, Alves, Abecasis and Br&#x00ED;gido</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec id="sec1">
<title>Background</title>
<p>Molecular epidemiology techniques allow us to track the HIV-1 transmission dynamics. Herein, we combined genetic, clinical and epidemiological data collected during routine clinical treatment to evaluate the dynamics and characteristics of transmission clusters of the most prevalent HIV-1 subtypes in the state of S&#x00E3;o Paulo, Brazil.</p>
</sec>
<sec id="sec2">
<title>Methods</title>
<p>This was a cross-sectional study conducted with 2,518 persons living with HIV (PLWH) from 53 cities in S&#x00E3;o Paulo state between Jan 2004 to Feb 2015. The phylogenetic tree of protease/reverse transcriptase (PR/RT) regions was reconstructed by PhyML and ClusterPicker used to infer the transmission clusters based on Shimodaira&#x2013;Hasegawa (SH) greater than 90% (phylogenetic support) and genetic distance less than 6%.</p>
</sec>
<sec id="sec3">
<title>Results</title>
<p>Of a total of 2,518 sequences, 2,260 were pure subtypes at the PR/RT region, being B (88%), F1 (8.1%), and C (4%). About 21.2% were na&#x00EF;ve with a transmitted drug resistance (TDR) rate of 11.8%. A total of 414 (18.3%) of the sequences clustered. These clusters were less evident in subtype B (17.7%) and F1 (15.1%) than in subtype C (40.2%). Clustered sequences were from PLWH at least 5&#x2009;years younger than non-clustered among subtypes B (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.001) and C (<italic>p</italic>&#x2009;=&#x2009;0.037). Men who have sex with men (MSM) predominated the cluster in subtype B (51%), C (85.7%), and F1 (63.6%; <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05). The TDR rate in clustered patients was 15.4, 13.6, and 3.1% for subtypes B, F1, and C, respectively. Most of the infections in subtypes B (80%), C (64%), and F1 (59%) occurred within the state of S&#x00E3;o Paulo. The metropolitan area of S&#x00E3;o Paulo presented a high level of endogenous clustering for subtypes B and C. The S&#x00E3;o Paulo city had 46% endogenous clusters of subtype C.</p>
</sec>
<sec id="sec4">
<title>Conclusion</title>
<p>Our findings showed that MSM, antiretroviral therapy in Treatment-Naive (ART-na&#x00EF;ve) patients, and HIV1-C, played an important role in the HIV epidemic in the S&#x00E3;o Paulo state. Further studies in transmission clusters are needed to guide the prevention intervention.</p>
</sec>
</abstract>
<kwd-group>
<kwd>HIV-1</kwd>
<kwd>genetic diversity</kwd>
<kwd>transmission clusters</kwd>
<kwd>S&#x00E3;o Paulo</kwd>
<kwd>Brazil</kwd>
</kwd-group>
<contract-sponsor id="cn1">FAPESP<named-content content-type="fundref-id">10.13039/501100001807</named-content></contract-sponsor>
<contract-sponsor id="cn2">Calouste Gulbenkian Foundation<named-content content-type="fundref-id">10.13039/501100000348</named-content></contract-sponsor>
<counts>
<fig-count count="1"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="46"/>
<page-count count="11"/>
<word-count count="7832"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Infectious Diseases: Epidemiology and Prevention</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec5">
<label>1</label>
<title>Introduction</title>
<p>S&#x00E3;o Paulo is the most populous State in Brazil and the driving force of the Brazilian economy, with an estimated population of 44,396,484 inhabitants in 2015 (21.6% of the Brazilian population and a third of the National grass product). The metropolitan area of S&#x00E3;o Paulo comprises 39 cities, and that of Campinas, 42 cities, corresponding to 47.8 and 9.6% of the state&#x2019;s population, respectively.<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref> In S&#x00E3;o Paulo State, 236,434 AIDS cases were reported from 1980 to 2014. In 2015, a total of 1,137 new HIV infections were reported in S&#x00E3;o Paulo city (<xref ref-type="bibr" rid="ref1">1</xref>).</p>
<p>HIV commonly spreads more rapidly in specific groups, such as those men who have sex with men (MSM), sex workers and people who inject drugs. According to the national epidemiological report, since 2008, the HIV epidemic has shown a significant increase in the number of cases among MSM. In the 18&#x2013;24 age group, the proportion increased from 30.2% in 2007 to 43.7% in 2012 (<xref ref-type="bibr" rid="ref2">2</xref>).</p>
<p>The HIV-1 epidemic in S&#x00E3;o Paulo is dynamic with a genetic complexity driven by subtypes B, F1 and recombinant BF1 (<xref ref-type="bibr" rid="ref3 ref4 ref5 ref6">3&#x2013;6</xref>), however recent studies have shown a continuous increase of subtype C among S&#x00E3;o Paulo patients (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref8">8</xref>). The Brazilian government has been sponsoring a large-scale implementation of highly active antiretroviral therapy (HAART) since December 1996 and until June 2013, approximately 400,000 patients were receiving HAART in Brazil (<xref ref-type="bibr" rid="ref9">9</xref>). The HAART improves the quality of life of the people living with HIV (PLWH) globally, however, virological failure when using HAART can lead to the emergence of drug resistance mutations (DRM) that increase the chance of new infections with resistant strains (<xref ref-type="bibr" rid="ref10">10</xref>). Most studies conducted in Brazil have shown a transmitted drug resistance (TDR) prevalence similar to that observed among developed countries (<xref ref-type="bibr" rid="ref11">11</xref>) and S&#x00E3;o Paulo follows this trend with around 8% of TDR reported (<xref ref-type="bibr" rid="ref12">12</xref>).</p>
<p>Although several studies have been conducted in S&#x00E3;o Paulo State, the dynamics and determinants of transmission clusters of HIV-1 subtypes prevalent in the state of S&#x00E3;o Paulo remain unknown and deserve further investigation. In the present study, we combined clinical and epidemiological data in order to evaluate the dynamics and determinants of transmission clusters of the prevalent HIV-1 subtypes in the state of S&#x00E3;o Paulo, Brazil.</p>
</sec>
<sec sec-type="materials|methods" id="sec6">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec7">
<label>2.1</label>
<title>Study design and setting</title>
<p>This was a cross-sectional study conducted with 2,518 PLWH from 53 cities in S&#x00E3;o Paulo state from 2004 to 2015. We included volunteers seeking genotype tests due to antiretroviral treatment (ART) failure and pre-treatment tests of newly diagnosed patients in two sites in the S&#x00E3;o Paulo metropolitan area. Blood samples were collected from consenting participants between Jan 2004 to Feb 2015 and sent to the Adolpho Lutz Institute (IAL) in S&#x00E3;o Paulo for a genotypic-resistance test. Moreover, a questionnaire was used to collect demographic, geographic, and clinical data [The CD4 T cell counts were obtained with Flow cytometry (BD, United States) and HIV plasma viral load was quantified using the contemporary methodology available at public HIV-1 viral load laboratory network including Branched DNA (Siemens, United States), NASBA (Nucleic Acid Sequence Based Amplification, United States) or real-time PCR (Abbott, United States)]. when available from each patient. Data was anonymized for these analyses, after reporting genotype results to clinical services to subsidize clinical decisions. The study was approved by the institutional ethical committee (CAAE 02298012.6.1001.0059).</p>
</sec>
<sec id="sec8">
<label>2.2</label>
<title>HIV-1 sequencing, subtyping, and phylogenetic analysis</title>
<p>Partial HIV-1 <italic>pol</italic> sequences for blood samples were obtained by population sequencing using in-house protocols (<xref ref-type="bibr" rid="ref12">12</xref>) or TruGene (Siemens, United States). The Pol amplicon encompassed the entire protease region and the first 230 amino acids of the reverse transcriptase, derived from 5 to 8 primers (both forward and reverse) to span the targeted sequence. For clinical applications, partial genomes were generated, and corresponding reports were sent to clinical services. However, for the purposes of this study, only sequences that met stringent quality control standards were included in the analysis The nucleotide sequences were subtyped using REGA v3.0 (<xref ref-type="bibr" rid="ref13">13</xref>), Comet (<xref ref-type="bibr" rid="ref14">14</xref>), SCUEL (<xref ref-type="bibr" rid="ref15">15</xref>), and jPHMM (<xref ref-type="bibr" rid="ref16">16</xref>). The sequences were submitted to the Los Alamos Quality Control tool, which can be accessed at the following URL.<xref ref-type="fn" rid="fn0002"><sup>2</sup></xref> Sequences containing more than three frame-shift events or stop-codons were removed, along with those classified as hypermutated. We split the sequences, according to purity, into subtypes B, C and F1. We then selected 2,107 unique background control sequences by blasting our sequences against the Los Alamos database<xref ref-type="fn" rid="fn0003"><sup>3</sup></xref> and the HIV database from Portugal consists of a repository of genetic sequences from the <italic>pol</italic> gene, obtained through antiretroviral resistance tests (PTHIVDB) conducted at Portugal&#x2019;s main hospital, Centro Hospitalar Lisboa Ocidental (CHLO). For each subtype, we aligned our sequences against the 10 closest global background sequences selected with Blast using muscle.<xref ref-type="fn" rid="fn0004"><sup>4</sup></xref> A preliminary phylogenetic analysis was done using a FastTree maximum-likelihood (ML) tree using the general time reversible (GTR) model nucleotide substitution (<xref ref-type="bibr" rid="ref17">17</xref>). The codons associated with DRMs for surveillance were manually removed from the sequence alignment to prevent the possibility of clustering due to mutations selected by the current use of antiretroviral therapy. To analyze HIV-1 transmission dynamics, phylogenetic reconstructions were performed by ML criterion using RAxML version 7.4.8 (<xref ref-type="bibr" rid="ref18">18</xref>) under the GTR&#x2009;+&#x2009;&#x0393; model without partitions. Cluster Picker was used to define transmission clusters as those clusters with bootstrap support &#x2265;90 and genetic distance &#x2265;6.0% (<xref ref-type="bibr" rid="ref19">19</xref>).</p>
</sec>
<sec id="sec9">
<label>2.3</label>
<title>Geographic cluster dynamics inter and intra S&#x00E3;o Paulo state</title>
<p>Based on the origin of the outpatient service, clusters that contained &#x2265;66% sequences with the same area from S&#x00E3;o Paulo State were classified as endogenous clusters. In the case of clusters with only two sequences, both must have been from the same locality to define an endogenous cluster. Outside clusters were referred to those with more than 34% of sequences from different areas.</p>
</sec>
<sec id="sec10">
<label>2.4</label>
<title>HIV-1 drug resistance analysis</title>
<p>The partial HIV-1 <italic>pol</italic> sequences containing PR/RT regions were screened for the presence of DRMs using the Calibrated Population Resistance tool available,<xref ref-type="fn" rid="fn0005"><sup>5</sup></xref> updated in 2016, according to the WHO&#x2019;s Surveillance Drug Resistance Mutation (SDRM) 2009 list (<xref ref-type="bibr" rid="ref20">20</xref>).</p>
</sec>
<sec id="sec11">
<label>2.5</label>
<title>Statistical analysis</title>
<p>Descriptive statistics such as frequencies with percentages and medians with interquartile range (IQR) were used to summarize patients&#x2019; demographic and clinic characteristics. We use the Shapiro&#x2013;Wilk test to check the normal distribution in order to choose parametric or non-parametric tests. Mann&#x2013;Whitney U or Kruskal-Wallis nonparametric tests were used to compare two or more independent groups. Differences between proportions were calculated with the Chi-square test or Fisher&#x2019;s exact test, as appropriate. We consider a significance level of 5% for all statistical analyses. The analysis was performed using SPSS v22 (IBM SPSS Statistics, United States).</p>
</sec>
</sec>
<sec sec-type="results" id="sec12">
<label>3</label>
<title>Results</title>
<sec id="sec13">
<label>3.1</label>
<title>Demographic and clinical characteristics</title>
<p>A total of 2,518 eligible sequences were studied, most of the cases (71.6%) from the S&#x00E3;o Paulo metropolitan area. After sequence quality control, 25 (1.1%) of them were removed. All sequences with a recombinant signal were removed from the analysis (10.8%, 233/2518). Thus, 2,260 sequences from patients infected with subtypes B, C and F1 were kept for further analysis. <xref ref-type="table" rid="tab1">Table 1</xref> summarizes the demographic and clinical characteristics of the studied population. The median age of the 2,260 patients included was 38 (IQR: 30&#x2013;46), of these, 65.1% were male. Heterosexuals (HET; 60.7%) and MSM (30.1%) were the most predominant. About 78.8% of patients were already on antiretroviral therapy and 21.2% were ART-na&#x00EF;ve (with a TDR rate of around 11.8%). The median values of CD4 cell count and log10 viral load were 274 (IQR: 141&#x2013;459) and 4.38 (IQR: 3.79&#x2013;4.95), respectively. Regarding HIV-1 subtyping, subtype B (88.2%) was the most predominant, followed by subtypes F1 (8.19%) and subtype C (3.63%). Individuals infected by subtype C were 4 and 6&#x2009;years younger than individuals infected by subtypes B and F1, respectively (<italic>p</italic>&#x2009;=&#x2009;0.020). Statistically significant differences were also observed between the distribution of subtypes with treatment status (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.001) and borderline for infection risk categories (<italic>p</italic>&#x2009;=&#x2009;0.053). The differences in mean CD4+ T cell count values between subtypes B (268 cells/mm3), C (395 cells/mm3) and F1 (303 cells/mm3) were statistically significant (<italic>p</italic>&#x2009;=&#x2009;0.004). On the other hand, although it was not statistically significant (<italic>p</italic>&#x2009;&#x003E;&#x2009;0.05), a high prevalence of TDR was observed in subtypes F1 (18.2%) and B (12.2%), while a lower prevalence was observed in subtype C (3.8%).</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Epidemiological characteristics and clinical data among HIV-1 positive patients from S&#x00E3;o Paulo by subtype.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Independent variables</th>
<th align="center" valign="top"><italic>N</italic>&#x2009;=&#x2009;2,260</th>
<th align="center" valign="top">Subtype B (<italic>N</italic>&#x2009;=&#x2009;1993, 88.2%)</th>
<th align="center" valign="top">Subtype C (<italic>N</italic>&#x2009;=&#x2009;82, 3.63%)</th>
<th align="center" valign="top">Subtype F1 (<italic>N</italic>&#x2009;=&#x2009;185, 8.19%)</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="bottom">Age median (IQR)</td>
<td align="center" valign="bottom">38 (30&#x2013;46)</td>
<td align="center" valign="bottom">38 (30&#x2013;46)</td>
<td align="center" valign="bottom">34 (28&#x2013;42)</td>
<td align="center" valign="bottom">40 (31&#x2013;45)</td>
<td align="center" valign="bottom"><bold>0.020</bold></td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="6">Gender, n (%)</td>
</tr>
<tr>
<td align="left" valign="bottom">Male</td>
<td align="center" valign="bottom">1,392 (65.1)</td>
<td align="center" valign="bottom">1,248 (65.8)</td>
<td align="center" valign="bottom">53 (71.6)</td>
<td align="center" valign="bottom">91 (53.8)</td>
<td align="center" valign="bottom"><bold>0.004</bold></td>
</tr>
<tr>
<td align="left" valign="bottom">Female</td>
<td align="center" valign="bottom">747 (34.9)</td>
<td align="center" valign="bottom">648 (34.2)</td>
<td align="center" valign="bottom">21 (28.4)</td>
<td align="center" valign="bottom">78 (46.2)</td>
<td/>
</tr>
<tr>
<td align="left" valign="bottom" colspan="6">Risk Factor, n (%)</td>
</tr>
<tr>
<td align="left" valign="bottom">HET</td>
<td align="center" valign="bottom">753 (60.7)</td>
<td align="center" valign="bottom">688 (61.9)</td>
<td align="center" valign="bottom">24 (41.4)</td>
<td align="center" valign="bottom">41 (56.9)</td>
<td align="center" valign="bottom">0.053&#x002A;</td>
</tr>
<tr>
<td align="left" valign="bottom">MSM</td>
<td align="center" valign="bottom">373 (30.1)</td>
<td align="center" valign="bottom">319 (28.7)</td>
<td align="center" valign="bottom">34 (58.6)</td>
<td align="center" valign="bottom">20 (27.8)</td>
<td/>
</tr>
<tr>
<td align="left" valign="bottom">PWID</td>
<td align="center" valign="bottom">17 (1.4)</td>
<td align="center" valign="bottom">17 (1.5)</td>
<td align="center" valign="bottom">0 (0.0)</td>
<td align="center" valign="bottom">0 (0.0)</td>
<td/>
</tr>
<tr>
<td align="left" valign="bottom">MTCT</td>
<td align="center" valign="bottom">98 (7.9)</td>
<td align="center" valign="bottom">87 (7.8)</td>
<td align="center" valign="bottom">0 (0.0)</td>
<td align="center" valign="bottom">11 (15.3)</td>
<td/>
</tr>
<tr>
<td align="left" valign="bottom" colspan="6">Therapy status, n (%)</td>
</tr>
<tr>
<td align="left" valign="bottom">Na&#x00EF;ve</td>
<td align="center" valign="bottom">427 (21.2)</td>
<td align="center" valign="bottom">353 (19.7)</td>
<td align="center" valign="bottom">52 (68.4)</td>
<td align="center" valign="bottom">22 (14.3)</td>
<td align="center" valign="bottom"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="bottom">Treated</td>
<td align="center" valign="bottom">1,591 (78.8)</td>
<td align="center" valign="bottom">1,435 (80.3)</td>
<td align="center" valign="bottom">24 (31.6)</td>
<td align="center" valign="bottom">132 (85.7)</td>
<td/>
</tr>
<tr>
<td align="left" valign="bottom">TDR, n (%)</td>
<td align="center" valign="bottom">49 (11.8)</td>
<td align="center" valign="bottom">43 (12.2)</td>
<td align="center" valign="bottom">2 (3.8)</td>
<td align="center" valign="bottom">4 (18.2)</td>
<td align="center" valign="bottom">0.982</td>
</tr>
<tr>
<td align="left" valign="bottom">CD4 median (IQR)</td>
<td align="center" valign="bottom">274 (141&#x2013;459)</td>
<td align="center" valign="bottom">268 (136&#x2013;452)</td>
<td align="center" valign="bottom">395 (204&#x2013;577)</td>
<td align="center" valign="bottom">303 (175&#x2013;504)</td>
<td align="center" valign="bottom"><bold>0.004</bold></td>
</tr>
<tr>
<td align="left" valign="bottom">VL (log<sub>10</sub>) median (IQR)</td>
<td align="center" valign="bottom">4.38 (3.79&#x2013;4.95)</td>
<td align="center" valign="bottom">4.30 (3.79&#x2013;4.94)</td>
<td align="center" valign="bottom">4.45 (3.69&#x2013;5.20)</td>
<td align="center" valign="bottom">4.39 (3.70&#x2013;4.98)</td>
<td align="center" valign="bottom">0.716</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>IQR, Interquartile range; HET, heterosexual; MSM, men who have sex with men; PWID, persons who inject drugs; MTCT, Mother-to-child transmission; VL, Viral Load (Log10). Bold numbers mean that results were statistically significant to the Kruskal Wallis test or Chi-square or the alternative &#x002A;Fisher exact test (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05).</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec14">
<label>3.2</label>
<title>Demographic and clinical profile of ART-na&#x00EF;ve and experienced patients</title>
<p>The characteristics related to ART-naive and experienced patients are described in <xref ref-type="table" rid="tab2">Table 2</xref>. ART-naive patients were 10&#x2009;years younger than ART-experienced patients in subtypes B or C and 6&#x2009;years younger in subtype F1. The distribution of sex between ART-na&#x00EF;ve and treated patients was statistically significant within subtype B (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.001) and C (<italic>p</italic>&#x2009;=&#x2009;0.020). The transmission route depending on the treatment status (na&#x00EF;ve vs. treated) was significant in all subtypes, whether B, C or F1 (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05). MSM patients predominated the na&#x00EF;ve population, whether those infected with subtype B (74%), subtype C (71.7%) and F1 (57.1%; <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05). The CD4+ T cell count in ART-na&#x00EF;ve patients (ranging from 464 to 545 cells/mm3) was higher than that observed in ART-experienced patients (ranging from 204 to 285 cells/mm3), regardless of HIV-1 subtypes (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05).</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Epidemiological data of HIV-1 positive patients from S&#x00E3;o Paulo by subtype according to therapy.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle" rowspan="2">Independent variables</th>
<th align="center" valign="middle" colspan="4">Subtype B (<italic>N</italic>&#x2009;=&#x2009;1788)</th>
<th align="center" valign="middle" colspan="4">Subtype C (<italic>N</italic>&#x2009;=&#x2009;82)</th>
<th align="center" valign="middle" colspan="4">Subtype F1 (F1&#x2009;=&#x2009;185)</th>
</tr>
<tr>
<th align="center" valign="top">Na&#x00EF;ve (<italic>N</italic>&#x2009;=&#x2009;353)</th>
<th align="center" valign="top">Treated (<italic>N</italic>&#x2009;=&#x2009;1,435)</th>
<th align="center" valign="top">Total</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
<th align="center" valign="top">Na&#x00EF;ve (<italic>N</italic>&#x2009;=&#x2009;52)</th>
<th align="center" valign="top">Treated (<italic>N</italic>&#x2009;=&#x2009;24)</th>
<th align="center" valign="top">Total</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
<th align="center" valign="top">Na&#x00EF;ve (<italic>N</italic>&#x2009;=&#x2009;22)</th>
<th align="center" valign="top">Treated (<italic>N</italic>&#x2009;=&#x2009;124)</th>
<th align="center" valign="top">Total</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Age, median (IQR)</td>
<td align="center" valign="middle">30 (25&#x2013;38)</td>
<td align="center" valign="middle">40 (32&#x2013;47)</td>
<td align="center" valign="middle">38 (30&#x2013;46)</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle">31.5 (28&#x2013;38.5)</td>
<td align="center" valign="middle">40 (31&#x2013;46)</td>
<td align="center" valign="middle">34 (28&#x2013;42)</td>
<td align="center" valign="middle"><bold>0.012</bold></td>
<td align="center" valign="middle">34 (26&#x2013;47.5)</td>
<td align="center" valign="middle">40.5 (33&#x2013;45)</td>
<td align="center" valign="middle">34 (28&#x2013;42)</td>
<td align="center" valign="middle">0.334</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="13">Sex, n (%)</td>
</tr>
<tr>
<td align="left" valign="middle">Male</td>
<td align="center" valign="middle">292 (83.7)</td>
<td align="center" valign="middle">864 (62.1)</td>
<td align="center" valign="middle">1,156 (66.4)</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle">41 (80.4)</td>
<td align="center" valign="middle">10 (52.6)</td>
<td align="center" valign="middle">51 (72.9)</td>
<td align="center" valign="middle"><bold>0.020</bold></td>
<td align="center" valign="middle">15 (68.2)</td>
<td align="center" valign="middle">64 (51.6)</td>
<td align="center" valign="middle">79 (54.1)</td>
<td align="center" valign="middle">0.151</td>
</tr>
<tr>
<td align="left" valign="middle">Female</td>
<td align="center" valign="middle">57 (16.3)</td>
<td align="center" valign="middle">528 (37.9)</td>
<td align="center" valign="middle">585 (33.6)</td>
<td/>
<td align="center" valign="middle">10 (19.6)</td>
<td align="center" valign="middle">9 (47.4)</td>
<td align="center" valign="middle">19 (27.1)</td>
<td/>
<td align="center" valign="middle">7 (31.8)</td>
<td align="center" valign="middle">60 (48.4)</td>
<td align="center" valign="middle">67 (45.9)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle" colspan="13">Transmission route, n (%)</td>
</tr>
<tr>
<td align="left" valign="middle">HET</td>
<td align="center" valign="middle">74 (23.2)</td>
<td align="center" valign="middle">550 (76.6)</td>
<td align="center" valign="middle">624 (60.2)</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle">13 (28.3)</td>
<td align="center" valign="middle">9 (90.0)</td>
<td align="center" valign="middle">22 (39.3)</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle">8 (38.1)</td>
<td align="center" valign="middle">26 (60.5)</td>
<td align="center" valign="middle">34 (53.1)</td>
<td align="center" valign="middle"><bold>0.002</bold></td>
</tr>
<tr>
<td align="left" valign="middle">MSM</td>
<td align="center" valign="middle">236 (74)</td>
<td align="center" valign="middle">73 (10.2)</td>
<td align="center" valign="middle">309 (29.8)</td>
<td/>
<td align="center" valign="middle">33 (71.7)</td>
<td align="center" valign="middle">1 (10.0)</td>
<td align="center" valign="middle">34 (60.7)</td>
<td/>
<td align="center" valign="middle">12 (57.1)</td>
<td align="center" valign="middle">7 (16.3)</td>
<td align="center" valign="middle">19 (29.7)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">PWID</td>
<td align="center" valign="middle">1 (0.3)</td>
<td align="center" valign="middle">16 (2.2)</td>
<td align="center" valign="middle">17 (1.6)</td>
<td/>
<td align="center" valign="middle">0 (0.0)</td>
<td align="center" valign="middle">0 (0.0)</td>
<td align="center" valign="middle">0 (0.0)</td>
<td/>
<td align="center" valign="middle">0 (0.0)</td>
<td align="center" valign="middle">0 (0.0)</td>
<td align="center" valign="middle">0 (0.0)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">MTCT</td>
<td align="center" valign="middle">8 (2.5)</td>
<td align="center" valign="middle">79 (11)</td>
<td align="center" valign="middle">87 (8.4)</td>
<td/>
<td align="center" valign="middle">0 (0.0)</td>
<td align="center" valign="middle">0 (0.0)</td>
<td align="center" valign="middle">0 (0.0)</td>
<td/>
<td align="center" valign="middle">1 (4.8)</td>
<td align="center" valign="middle">10 (23.3)</td>
<td align="center" valign="middle">11 (17.2)</td>
<td/>
</tr>
<tr>
<td align="left" valign="middle">DRMs, n (%)</td>
<td align="center" valign="middle">43 (12.2)</td>
<td align="center" valign="middle">1,260 (87.8)</td>
<td align="center" valign="middle">1,303(72.9)</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle">2 (3.8)</td>
<td align="center" valign="middle">20 (83.3)</td>
<td align="center" valign="middle">22 (28.9)</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle">4 (18.2)</td>
<td align="center" valign="middle">113 (85.6)</td>
<td align="center" valign="middle">117 (76)</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">CD4, median (IQR)</td>
<td align="center" valign="middle">464 (324&#x2013;642)</td>
<td align="center" valign="middle">241 (117&#x2013;404)</td>
<td align="center" valign="middle">268 (136&#x2013;452)</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle">545 (400.2&#x2013;703)</td>
<td align="center" valign="middle">204 (106&#x2013;274)</td>
<td align="center" valign="middle">395 (204&#x2013;577)</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle">526 (282&#x2013;673.7)</td>
<td align="center" valign="middle">285 (157&#x2013;454)</td>
<td align="center" valign="middle">395 (204&#x2013;577)</td>
<td align="center" valign="middle"><bold>0.003</bold></td>
</tr>
<tr>
<td align="left" valign="middle">VL (log<sub>10</sub>), median<break/>(IQR)</td>
<td align="center" valign="middle">4.39 (3.18&#x2013;4.89)</td>
<td align="center" valign="middle">4.40 (3.82&#x2013;4.95)</td>
<td align="center" valign="middle">4.37 (3.79&#x2013;4.94)</td>
<td align="center" valign="middle">0.874</td>
<td align="center" valign="middle">4.31 (3.45&#x2013;5.22)</td>
<td align="center" valign="middle">4.52 (4.08&#x2013;5.21)</td>
<td align="center" valign="middle">4.45 (3.69&#x2013;5.20)</td>
<td align="center" valign="middle">0.820</td>
<td align="center" valign="middle">4.42 (3.57&#x2013;5.3)</td>
<td align="center" valign="middle">4.5 (3.72&#x2013;4.9)</td>
<td align="center" valign="middle">4.45 (3.69&#x2013;5.2)</td>
<td align="center" valign="middle">0.899</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>IQR, Interquartile range; HET, heterosexual; MSM, men who have sex with men; PWID, persons who inject drugs; MTCT, Mother-to-child transmission; VL, Viral Load (Log10). Bold numbers mean that results were statistically significant to the Kruskal Wallis test or Chi-square or the alternative &#x002A;Fisher exact test (<italic>p</italic> &#x003C;&#x2009;0.05).</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec15">
<label>3.3</label>
<title>Features of transmission clusters of HIV-1 subtypes</title>
<p>The dynamics and demographic characteristics related to HIV-1 subtype transmission clusters are presented in <xref ref-type="table" rid="tab3">Table 3</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Data S1</xref><xref ref-type="supplementary-material" rid="SM1">&#x2013;S3</xref>. About 18.3% (414/2260) of the sequences clustered with one or more other sequences. This clustering was less pronounced in subtypes B (17.7%) and F1 (15.1), compared to C (40.2%). The median age was significantly associated with clustering for subtypes B (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.001) and C (<italic>p</italic>&#x2009;=&#x2009;0.037). The median age of clustered individuals for subtype B (33&#x2009;years, IQR:26&#x2013;41) was 6&#x2009;years younger than the non-clustered individuals (39&#x2009;years, IQR: 31&#x2013;47). In subtype C, the median age of clustered individuals (30&#x2009;years, IQR: 27&#x2013;32) was 5&#x2009;years younger than the non-clustered group (35&#x2009;years, IQR, 30&#x2013;45). The clustering of patients was related to sex, in patients infected with subtype B (<italic>p</italic>&#x2009;=&#x2009;0.001) and C (<italic>p</italic>&#x2009;=&#x2009;0.012). Within individuals in the transmission cluster, the proportion of males was higher for subtypes B (73.7%, <italic>p</italic>&#x2009;=&#x2009;0.001), C (71.6%, <italic>p</italic>&#x2009;=&#x2009;0.012) and F1 (68%, albeit without no statistical significance observed, <italic>p</italic>&#x2009;=&#x2009;0.124). Among the subtype B clusters, 51% were MSM, 41.4% HET, 6% mother-to-child transmission (MTCT), and 1.3% persons who inject drugs (PWID; <italic>p</italic>&#x2009;&#x003C;&#x2009;0.001). In subtype C, 85.7% of the clusters were composed of MSM patients and 14.3% HET (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.001). Within subtype F1 clusters, 63.6% were MSM and 36.4% HET (<italic>p</italic>&#x2009;=&#x2009;0.011). Dyads clusters were frequently observed in patients grouped with subtype B (68%) and F1 (53.6%) while patients grouped with subtype C presented clusters with 3 or more sequences. The TDR rate in clustered patients from subtype B was 15.4%, for subtype C was 3.1% and subtype F1 was 13.6%, although no statistical difference was observed when compared to non-clustered patients of the same HIV-1 subtypes (<italic>p</italic>&#x2009;&#x003E;&#x2009;0.05). The difference in CD4+ T cell counts was significant, comparing clustered to non-clustered patients only from subtype C (<italic>p</italic>&#x2009;=&#x2009;0.003).</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Epidemiological and clinical data of HIV-1 positive patients based on transmission clusters (<italic>N</italic>&#x2009;=&#x2009;414) by subtype.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" rowspan="2">Independent variables</th>
<th align="center" valign="top" colspan="4">Subtype B (<italic>N</italic>&#x2009;=&#x2009;1993)</th>
<th align="center" valign="top" colspan="4">Subtype C (<italic>N</italic>&#x2009;=&#x2009;82)</th>
<th align="center" valign="top" colspan="4">Subtype F1 (<italic>N</italic>&#x2009;=&#x2009;185)</th>
</tr>
<tr>
<th align="center" valign="top">Non-cluster (<italic>N</italic>&#x2009;=&#x2009;1,640)</th>
<th align="center" valign="top">Cluster (<italic>N</italic>&#x2009;=&#x2009;353, 17.7%)</th>
<th align="center" valign="top">Total (<italic>N</italic>&#x2009;=&#x2009;1993)</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
<th align="center" valign="top">Non-cluster (<italic>N</italic>&#x2009;=&#x2009;49)</th>
<th align="center" valign="top">Cluster (<italic>N</italic>&#x2009;=&#x2009;33, 40.2%)</th>
<th align="center" valign="top">Total (<italic>N</italic>&#x2009;=&#x2009;82)</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
<th align="center" valign="top">Non-cluster (<italic>N</italic>&#x2009;=&#x2009;157)</th>
<th align="center" valign="top">Cluster (<italic>N</italic>&#x2009;=&#x2009;28, 15.1%)</th>
<th align="center" valign="top">Total (<italic>N</italic>&#x2009;=&#x2009;185)</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="bottom">Age median (IQR)</td>
<td align="center" valign="bottom">39 (31&#x2013;47)</td>
<td align="center" valign="bottom">33 (26&#x2013;41)</td>
<td align="center" valign="bottom">38 (30&#x2013;46)</td>
<td align="center" valign="bottom"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="bottom">35 (30&#x2013;45)</td>
<td align="center" valign="bottom">30 (27&#x2013;37)</td>
<td align="center" valign="bottom">34 (28&#x2013;42)</td>
<td align="center" valign="bottom"><bold>0.037</bold></td>
<td align="center" valign="bottom">40 (31&#x2013;45)</td>
<td align="center" valign="bottom">39.5 (29&#x2013;44.)</td>
<td align="center" valign="bottom">40 (31&#x2013;45)</td>
<td align="center" valign="bottom">0.987</td>
</tr>
<tr>
<td align="left" valign="bottom" colspan="13">Gender, n (%)</td>
</tr>
<tr>
<td align="left" valign="bottom">Male</td>
<td align="center" valign="bottom">1,002 (64.1)</td>
<td align="center" valign="bottom">246 (73.7)</td>
<td align="center" valign="bottom">1,248 (65.8)</td>
<td align="center" valign="bottom"><bold>0.001</bold></td>
<td align="center" valign="bottom">26 (60.5)</td>
<td align="center" valign="bottom">27 (87.1)</td>
<td align="center" valign="bottom">53 (71.6)</td>
<td align="center" valign="bottom"><bold>0.012</bold></td>
<td align="center" valign="bottom">74 (51.4)</td>
<td align="center" valign="bottom">17 (68)</td>
<td align="center" valign="bottom">91 (53.8)</td>
<td align="center" valign="bottom">0.124</td>
</tr>
<tr>
<td align="left" valign="bottom">Female</td>
<td align="center" valign="bottom">560 (35.9)</td>
<td align="center" valign="bottom">88 (26.3)</td>
<td align="center" valign="bottom">648 (34.2)</td>
<td/>
<td align="center" valign="bottom">17 (39.5)</td>
<td align="center" valign="bottom">4 (12.9)</td>
<td align="center" valign="bottom">21 (28.4)</td>
<td/>
<td align="center" valign="bottom">70 (48.6)</td>
<td align="center" valign="bottom">8 (32)</td>
<td align="center" valign="bottom">78 (46.2)</td>
<td/>
</tr>
<tr>
<td align="left" valign="bottom" colspan="13">Risk Factor, n (%)</td>
</tr>
<tr>
<td align="left" valign="bottom">HET</td>
<td align="center" valign="bottom">592 (67.3)</td>
<td align="center" valign="bottom">96 (41.4)</td>
<td align="center" valign="bottom">688 (61.9)</td>
<td align="center" valign="bottom"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="bottom">20 (66.7)</td>
<td align="center" valign="bottom">4 (14.3)</td>
<td align="center" valign="bottom">24 (41.4)</td>
<td align="center" valign="bottom"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="bottom">37 (60.7)</td>
<td align="center" valign="bottom">4 (36.4)</td>
<td align="center" valign="bottom">41 (56.9)</td>
<td align="center" valign="bottom"><bold>0.011&#x002A;</bold></td>
</tr>
<tr>
<td align="left" valign="bottom">MSM</td>
<td align="center" valign="bottom">200 (22.8)</td>
<td align="center" valign="bottom">119 (51.3)</td>
<td align="center" valign="bottom">319 (28.7)</td>
<td/>
<td align="center" valign="bottom">10 (33.3)</td>
<td align="center" valign="bottom">24 (85.7)</td>
<td align="center" valign="bottom">34 (58.6)</td>
<td/>
<td align="center" valign="bottom">13 (21.3)</td>
<td align="center" valign="bottom">7 (63.6)</td>
<td align="center" valign="bottom">20 (27.8)</td>
<td/>
</tr>
<tr>
<td align="left" valign="bottom">PWID</td>
<td align="center" valign="bottom">14 (1.6)</td>
<td align="center" valign="bottom">3 (1.3)</td>
<td align="center" valign="bottom">17 (1.5)</td>
<td/>
<td align="center" valign="bottom">0 (0)</td>
<td align="center" valign="bottom">0 (0)</td>
<td align="center" valign="bottom">0 (0)</td>
<td/>
<td align="center" valign="bottom">0 (0)</td>
<td align="center" valign="bottom">0 (0)</td>
<td align="center" valign="bottom">0 (0)</td>
<td/>
</tr>
<tr>
<td align="left" valign="bottom">MTCT</td>
<td align="center" valign="bottom">73 (8.3)</td>
<td align="center" valign="bottom">14 (6.0)</td>
<td align="center" valign="bottom">87 (7.8)</td>
<td/>
<td align="center" valign="bottom">0 (0)</td>
<td align="center" valign="bottom">0 (0)</td>
<td align="center" valign="bottom">0 (0)</td>
<td/>
<td align="center" valign="bottom">11 (18)</td>
<td align="center" valign="bottom">0 (0)</td>
<td align="center" valign="bottom">11 (15.3)</td>
<td/>
</tr>
<tr>
<td align="left" valign="bottom" colspan="13">Type of cluster, n (%)</td>
</tr>
<tr>
<td align="left" valign="bottom">Dyads clusters</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">240 (68)</td>
<td align="center" valign="bottom">240 (68)</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">16 (48.5)</td>
<td align="center" valign="bottom">16 (48.5)</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">15 (53.6)</td>
<td align="center" valign="bottom">15 (53.6)</td>
<td align="center" valign="bottom">-</td>
</tr>
<tr>
<td align="left" valign="bottom"><bold>&#x2265;</bold>3 sequences</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">113 (32)</td>
<td align="center" valign="bottom">113 (32)</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">17 (51.5)</td>
<td align="center" valign="bottom">17 (51.5)</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">-</td>
<td align="center" valign="bottom">13 (46.4)</td>
<td align="center" valign="bottom">13 (46.4)</td>
<td align="center" valign="bottom">-</td>
</tr>
<tr>
<td align="left" valign="bottom">TDR, n (%)</td>
<td align="center" valign="bottom">22 (10.0)</td>
<td align="center" valign="bottom">21 (15.4)</td>
<td align="center" valign="bottom">43 (12.2)</td>
<td align="center" valign="bottom">0.129</td>
<td align="center" valign="bottom">1 (2.3)</td>
<td align="center" valign="bottom">1 (3.1)</td>
<td align="center" valign="bottom">2 (2.4)</td>
<td align="center" valign="bottom">1.000&#x002A;</td>
<td align="center" valign="bottom">1 (7.1)</td>
<td align="center" valign="bottom">3 (13.6)</td>
<td align="center" valign="bottom">4 (18.2)</td>
<td align="center" valign="bottom">0.427<bold>&#x002A;</bold></td>
</tr>
<tr>
<td align="left" valign="bottom">CD4 median (IQR)</td>
<td align="center" valign="bottom">263 (131&#x2013;446)</td>
<td align="center" valign="bottom">299 (153&#x2013;516)</td>
<td align="center" valign="bottom">268 (136&#x2013;452)</td>
<td align="center" valign="bottom">0.392</td>
<td align="center" valign="bottom">262 (153&#x2013;448)</td>
<td align="center" valign="bottom">549 (371&#x2013;697)</td>
<td align="center" valign="bottom">395 (204&#x2013;577)</td>
<td align="center" valign="bottom"><bold>0.003</bold></td>
<td align="center" valign="bottom">294 (170&#x2013;500)</td>
<td align="center" valign="bottom">318 (194&#x2013;537)</td>
<td align="center" valign="bottom">303 (175&#x2013;504)</td>
<td align="center" valign="bottom">0.748</td>
</tr>
<tr>
<td align="left" valign="bottom">VL median (IQR)</td>
<td align="center" valign="bottom">4.37<break/>(3.79&#x2013;4.92)</td>
<td align="center" valign="bottom">4.39<break/>(3.81&#x2013;4.99)</td>
<td align="center" valign="bottom">4.30<break/>(3.79&#x2013;4.94)</td>
<td align="center" valign="bottom">0.372</td>
<td align="center" valign="bottom">4.31<break/>(3.45&#x2013;5.22)</td>
<td align="center" valign="bottom">4.52<break/>(4.08&#x2013;5.21)</td>
<td align="center" valign="bottom">4.45<break/>(3.69&#x2013;5.20)</td>
<td align="center" valign="bottom">0.254</td>
<td align="center" valign="bottom">4.39<break/>(3.72&#x2013;4.98)</td>
<td align="center" valign="bottom">4.42<break/>(3.57&#x2013;4.99)</td>
<td align="center" valign="bottom">4.39<break/>(3.70&#x2013;4.98)</td>
<td align="center" valign="bottom">0.940</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>IQR, Interquartile range; HET, heterosexual; MSM, men who have sex with men; PWID, persons who inject drugs; MTCT, Mother-to-child transmission; VL, Viral Load (Log10). Bold numbers mean that results were statistically significant to the Kruskal Wallis test or Chi-square or the alternative &#x002A;Fisher exact test (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05).</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec16">
<label>3.4</label>
<title>Clustering dynamics of HIV-1 subtypes</title>
<p>The dynamics of HIV-1 subtype clustering are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. It was observed that about 80% of subtype B infections occurred within the state of S&#x00E3;o Paulo, while 10% were associated with other Brazilian states and 8% with sequences from other countries. For subtype C, we found that 64% of transmissions occurred within the state of S&#x00E3;o Paulo while 18% were related to clusters of other Brazilian states and 18% clusters from other countries. In subtype F1, 59% of transmissions occurred within the state, 30% occurred in other Brazilian states and 11% were associated with other countries (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). To better understand micro-epidemics in the state of S&#x00E3;o Paulo, we divided the map of the state according to the geographic location, gathering nearby municipalities. We found that areas 1 (Northeast, NE) and 4 (Metropolitan, Metro), where most sequences originated, have a similar profile, with approximately 60% of subtype B of endogenous clusters, suggesting transmissions within these regions. For the subtype C in the area NE, about 30% of the transmissions occurred within this location, while in the Metropolitan area over 50% occurred within the area. The subtype F1 had a low presence of endogenous clusters in the aforementioned areas (1 and 4). Regarding areas 2 (Northwest, NW) and 3 (South, SO). Subtype B show a similar profile of about half of the sequences showing endogenous clusters but without the identification of endogenous clusters from subtypes C and F1 available sequences (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The metropolitan area of S&#x00E3;o Paulo contributed with the larger number of samples and represents the most important region within the state. We therefore further divided it into three sub-areas (S&#x00E3;o Paulo city, ABCD region and Periphery). The peripheral region of the Greater S&#x00E3;o Paulo (4A), showed a different profile for the origin of transmission clusters, compared to regions 4B and 4C. We find in this highly populated area a high level of endogenous clustering for subtypes B and C. It is noteworthy that the region of S&#x00E3;o Paulo city had about 46% of endogenous clusters of subtype C. Interestingly, the periphery region is responsible for about 33% of endogenous clustering of subtype F1, similar to that observed in area NE (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Types of Geographic clusters identified in patients from S&#x00E3;o Paulo State. The figure depicts cluster composition, by HIV-1 circulating subtype, according to the origin of sequences that compose the cluster as (i) Endogenous cluster (Blue bars) - cluster that includes at least 66% of its compounding members from the same geographical location, (ii) outside clusters, red bars, for clusters that are comprised of less than 66% of local cases. <bold>(1A)</bold> Further divides the outside clusters as clustering with foreign sequences (orange bar), from other countries, and those with only national (other states) clusters (red). <bold>(B)</bold> Shows the geographic division used to analyze the S&#x00E3;o Paulo State transmission cluster into 4 smaller areas. The zone highlighted in purple represents Area 1, yellow represents Area 2, the green zone represents Area 3 and the gray zone represents Area 4. <bold>(C)</bold> Zoom in S&#x00E3;o Paulo metropolitan area (zone 4). Light gray represents the periphery region of the metropolitan area, intermediate gray represents the major ABCD cities and dark gray represents S&#x00E3;o Paulo city.</p>
</caption>
<graphic xlink:href="fpubh-12-1384512-g001.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec17">
<label>4</label>
<title>Discussion</title>
<p>To improve the knowledge of the HIV-1 transmission dynamics in the state of S&#x00E3;o Paulo, Brazil, this study considered a large dataset that examines the demographic and clinical characteristics of individuals infected by the subtypes B, C and F1. The observed prevalence of HIV-1 subtypes was similar to that observed in previous studies in the region being the epidemic was driven by subtype B, followed by subtype F and the less frequent, subtype C (<xref ref-type="bibr" rid="ref21">21</xref>). However, when only patients with recent diagnoses (between January 2013 and February 2015) are considered, the frequency of subtype C is about 10%. This picture contrasts with that of the early 2000s when the prevalence of the subtype C in the region was approximately 3.8% (<xref ref-type="bibr" rid="ref4">4</xref>). This proportion is consistent with more recent studies on HIV-1 diversity, which report an increase in the subtype C in S&#x00E3;o Paulo (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref22">22</xref>). Another remarkable concern involving subtype C is the high proportion of ART-na&#x00EF;ve patients compared to ART-experienced patients, supporting the hypothesis of a more recent introduction of subtype C in the state of S&#x00E3;o Paulo (<xref ref-type="bibr" rid="ref23">23</xref>).</p>
<p>Our findings showed that subtype B had a lower median CD4 T-cell count compared to subtypes F1 and C, as also recorded in previous studies (<xref ref-type="bibr" rid="ref24">24</xref>), however, that comparison revealed no differences in viral load levels between the HIV-1 subtypes. This study has not performed any survival analyses on the three subtypes, though other authors have suggested an association between the viral subtype and progression to AIDS (<xref ref-type="bibr" rid="ref25 ref26 ref27 ref28">25&#x2013;28</xref>).</p>
<p>This study includes samples from 53 different cities of S&#x00E3;o Paulo state which is responsible for 32% of the Brazilian AIDS epidemic. Surveillance studies on primary resistance performed in Brazil estimated TDR prevalence between 5 to 15%, depending on the geographic region (<xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref29">29</xref>, <xref ref-type="bibr" rid="ref30">30</xref>). Another study conducted in 2015 detected a primary resistance rate of 9.2% in samples from patients with recent diagnoses in S&#x00E3;o Paulo state (<xref ref-type="bibr" rid="ref31">31</xref>). The current study found 11.8% of TDR, with a high rate of resistance observed in subtypes F1 (18.2%), followed by subtypes B (12.2%) and C (3.8%). Previous studies conducted in the South of Brazil and involving a cohort of ART-na&#x00EF;ve patients found a lower rate of DRM associated with resistance to subtype C compared to subtype B (<xref ref-type="bibr" rid="ref32">32</xref>). Though many studies performed in different Brazilian states have reported rates of primary resistance, there is still a lack of information on this rate among different high-risk groups. It is known that, in Brazil, the MSM population is 29 times more susceptible to being infected compared to the whole population (<xref ref-type="bibr" rid="ref33">33</xref>). In Latin America, MSM is the most commonly exposed to the risk of HIV-1 infection and represents the highest portion of new infections (<xref ref-type="bibr" rid="ref34">34</xref>). The study by Berm&#x00FA;dez-Aza et al. (<xref ref-type="bibr" rid="ref35">35</xref>), evaluated 299 HIV-infected MSM from 9 Brazilian cities and reported a rate of primary resistance of around 19.3% which was consistent with the data observed in the present study.</p>
<p>The concept of transmission clusters is controversial, and consensus has yet to be established. The definition of clusters adopted in this study was determined by bootstrap support &#x2265;90% and a genetic distance &#x2264;6.0%. Though many studies have adopted a genetic distance of up to 4.5%, we believe that the threshold adopted is necessarily more flexible, given the fact that our study considers 10&#x2009;years of the epidemic, during which time patients studied have been in different phases of the disease and with different time of within-host viral evolution. Therefore, our study detected a putative low cluster prevalence of 18.3%. This low cluster prevalence could be explained in part because we were conservative when defining the cluster using two approaches, genetic distance and branch support. We found statistical differences in the clustering when the three circulating subtypes were evaluated. In subtype C, 40% of the patients were found to be transmission clusters, a value much higher proportion than that found among the B and F1 subtypes. One hypothesis for this difference is the fact that subtype C was introduced more recently and is affected by the distance from the founder virus (<xref ref-type="bibr" rid="ref36">36</xref>, <xref ref-type="bibr" rid="ref37">37</xref>).</p>
<p>Studies using phylogenetics to describe transmission clusters are being increasingly used in developed countries. The study by Lewis et al. (<xref ref-type="bibr" rid="ref38">38</xref>) describes the HIV-1 transmission cluster in London where was reported that approximately 25% of the MSM population was associated with various clusters. Meanwhile, a study involving a heterosexual cohort in the United Kingdom reported that only 5% of the population studied was associated with transmission clusters (<xref ref-type="bibr" rid="ref39">39</xref>).</p>
<p>Based on our analysis of transmission clusters, it can be determined that, regardless of the viral subtype, clusters are most represented by the MSM and ART-na&#x00EF;ve patients that are driving the epidemic in S&#x00E3;o Paulo state. The individual risk factors experienced by MSM have been well documented. They include high frequencies of different partners, unprotected sex, and high-index viral loads (<xref ref-type="bibr" rid="ref40">40</xref>, <xref ref-type="bibr" rid="ref41">41</xref>). Another factor involved in MSM is the peculiar risk associated with anal sex, as the behaviors associated with it, increase the efficacy of viral transmission, resulting in a probability of HIV transmission via anal sex is 18 times higher than vaginal sex (<xref ref-type="bibr" rid="ref42">42</xref>).</p>
<p>Another interesting finding was that patients with primary resistance to subtypes B and F1 had higher associations with transmission clusters. Indeed, many individuals carrying the virus with TDR, even after removing the TDR codons, were linked to other patients, a finding that suggests domestication or endogenic transmission events. Paradoxically, the mutations associated with resistance that prevail in these clusters do not seem to reduce viral fitness highlighting the importance of pre-treatment genotype testing among recently diagnosed individuals when NNRTI-based regimens are being considered. In this line, a study involving a Swiss cohort found that ART-na&#x00EF;ve individuals are most commonly responsible for the transmission of resistant strains in the MSM (<xref ref-type="bibr" rid="ref43">43</xref>).</p>
<p>We observed that of the HIV epidemic in the state of S&#x00E3;o Paulo, 81% of the clusters in subtype B were found to be endogenous, 11% originated in other states, and 8% were from other countries. This finding may be explained by the relatively early introduction of this subtype in Brazil, which occurred in the 1960s (<xref ref-type="bibr" rid="ref44">44</xref>) as a result, the epidemic seems to be self-sustained. Among the subtypes studied, subtype C was found to be the most frequent in the cluster originating outside of Brazil; the clusters originating in southern Brazilian states were also found to have an important influence. This finding may also be explained by the recent introduction of subtype C into the state, as well as by the fact that this is the most prevalent subtype in the world (<xref ref-type="bibr" rid="ref45">45</xref>). Other analyses also support the origin of the subtype C in S&#x00E3;o Paulo from cities in the south of Brazil (<xref ref-type="bibr" rid="ref23">23</xref>). Subtype F1 was found to have an important portion of clusters originating in other Brazilian states and a low percentage of clusters from outside of Brazil, perhaps because of its low prevalence worldwide.</p>
<p>To further clarify the issue of transmission cluster origins within the state, we divided the state into four geopolitical regions. This division revealed that Regions Northeast and the Metropolitan area have very similar profiles. They reflected independent epidemics in which more than 50% of the subtype B clusters had local origins. These differences are likely caused by the fact that each of these regions possesses its independent economic centers and a relatively mature, even though concentrated epidemic. Subtype C was found to have an important component of endogenous clusters, particularly within the metropolitan area, and was also found to be associated with the MSM population. This finding is partially similar to reports in the South of Brazil, where the epidemic linked to this subtype is associated with both risk groups, the MSM and heterosexuals (<xref ref-type="bibr" rid="ref46">46</xref>). However, the Northwest and South regions differed from the others described above in that only subtype B was found to have an important proportion of endogenous clusters. This difference may be due to the underrepresentation of samples from the regions and/or to the low prevalence of non-B subtypes in this geographic region. However, we evaluated a large dataset from most of the regions analyzed. We take into account the reported number of HIV infections by geographic location. Thus, the percentage of HIV-1 infected patients by location follows the distribution: area 1 (Northeast, NE; 0.78%), area 2 (Northwest, NW; 0.72%), area 3 (SOUTH, SO; 0.4%) and area 4 (Metropolitan, Metro; 1.4%). Highlighting that the area with the lowest representation (area 3), which has its representation ranging from 0.4 to 0.7% if we exclude the city of Santos, which for logistical issues was not represented in our sample cohort.</p>
<p>Within the state of S&#x00E3;o Paulo, we found independent micro-epidemics, the strongest of which involve subtype B. We further subdivided the S&#x00E3;o Paulo metropolitan area, with a population of over 14 million into 3 different sub-regions in an attempt to understand the role of each region in the local epidemic. One particularly noteworthy finding was the fact that there were only endogenous clusters of subtype C in Region 4a (the ABCD region) and in Region 4c (the S&#x00E3;o Paulo city). It is very likely that this subtype was introduced into these two sub-regions independently and then spread independently. Meanwhile, the subtype F1 epidemic is largely confined to the periphery of the metropolitan area, among individuals in the neighborhood of the region (region 4b) and is likely to have spread from there to other areas within the city or the opposite but maintained a local spread.</p>
<p>We recognize the limitations of our study and a potential bias in the results. The most important of which is the sample bias, the data sampling method used, and the disproportionate amount of samples from the different cities within the state. Our research utilized sequences from the partial pol region of the HIV genome, which inherently restricts the assessment of phylogenetic signals and particularly impacts the identification of recombination events in other genomic regions. We also realize that phylogeographic and migration analyses could give us further insight into the concern of intra-city transmission. On the other hand, this study was performed based on genotyping services open to all public clinics in the State. Albeit limitations in sample transportation may have diminished the amount of samples from areas farther away from the laboratory, it probably did not impact the subtype distribution and other potential inclusion bias.</p>
</sec>
<sec sec-type="conclusions" id="sec18">
<label>5</label>
<title>Conclusion</title>
<p>Our data suggests that the epidemic in the state of S&#x00E3;o Paulo is driven by the MSM population with a higher level of TDR, regardless of the HIV-1 subtype, and that the epidemic is sustained by ART-na&#x00EF;ve patients. The prevalence of subtype C in the epidemic is growing in the state, particularly in the greater S&#x00E3;o Paulo metropolitan area, where individuals with subtype C infection are twice as likely to be in transmission cluster than those infected with subtypes B and F1.</p>
</sec>
<sec sec-type="data-availability" id="sec19">
<title>Data availability statement</title>
<p>The authors acknowledge that the data presented in this study must be deposited and made publicly available in an acceptable repository, prior to publication. Frontiers cannot accept a manuscript that does not adhere to our open data policies.</p>
</sec>
<sec sec-type="ethics-statement" id="sec20">
<title>Ethics statement</title>
<p>The studies involving humans were approved by The study was approved by the institutional ethical committee (CAAE 02298012.6.1001.0059). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec sec-type="author-contributions" id="sec21">
<title>Author contributions</title>
<p>VP: Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. AP-P: Data curation, Formal analysis, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. CS: Data curation, Formal analysis, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. JP: Data curation, Methodology, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. CA: Data curation, Methodology, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. MP: Data curation, Methodology, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. MM: Data curation, Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft. LC: Data curation, Methodology, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. EM: Data curation, Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft. DA: Data curation, Methodology, Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft. AA: Conceptualization, Data curation, Methodology, Resources, Supervision, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. LB: Conceptualization, Methodology, Project administration, Resources, Supervision, Validation, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec22">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by FAPESP (2013/19441&#x2013;7 and 2018/14.384&#x2013;9) and FCT MARVEL (PTDC/SAU-PUB/4018/2021) and by funds from FCT to GHTM-UID/04413/2020 and LA-REAL-LA/P/0117/2020, Calouste Gulbenkian Foundation (FCG), under the ENVOLVE Ci&#x00EA;ncia PALOP program that funded the HITOLA project. The funding body had no role in the design of the study, collection, analysis, interpretation of data, or in writing the manuscript.</p>
</sec>
<sec sec-type="COI-statement" id="sec23">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec sec-type="disclaimer" id="sec24">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec25">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fpubh.2024.1384512/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fpubh.2024.1384512/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.PDF" id="SM1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<fn-group>
<fn id="fn0001">
<p><sup>1</sup><ext-link xlink:href="https://www.ibge.gov.br/explica/pib.php" ext-link-type="uri">https://www.ibge.gov.br/explica/pib.php</ext-link></p>
</fn>
<fn id="fn0002">
<p><sup>2</sup><ext-link xlink:href="https://www.hiv.lanl.gov" ext-link-type="uri">https://www.hiv.lanl.gov</ext-link></p>
</fn>
<fn id="fn0003">
<p><sup>3</sup><ext-link xlink:href="https://www.hiv.lanl.gov/content/index" ext-link-type="uri">https://www.hiv.lanl.gov/content/index</ext-link></p>
</fn>
<fn id="fn0004">
<p><sup>4</sup><ext-link xlink:href="http://www.drive5.com/muscle" ext-link-type="uri">http://www.drive5.com/muscle</ext-link></p>
</fn>
<fn id="fn0005">
<p><sup>5</sup><ext-link xlink:href="https://hivdb.stanford.edu/cpr/form/PRRT/v8.1" ext-link-type="uri">https://hivdb.stanford.edu/cpr/form/PRRT/v8.1</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll1">Secretaria de Estado da Sa&#x00FA;de de S&#x00E3;o Paulo</collab></person-group>. BOLETIM EPIDEMIOL&#x00D3;GICO, CRT-PE-DST/AIDS/CVE, Secretaria de Estado da Sa&#x00FA;de de S&#x00E3;o Paulo, (<year>2015</year>) ANO XXXII, N<sup>o</sup> 1, per&#x00ED;odo de 1<sup>o</sup> de Julho de 2014 a 30 de Junho de 2015. 2015. Available from: <ext-link xlink:href="https://www.saude.sp.gov.br/resources/crt/vig.epidemiologica/boletim-epidemiologico-crt/boletim_2015_versao_final.pdf" ext-link-type="uri">https://www.saude.sp.gov.br/resources/crt/vig.epidemiologica/boletim-epidemiologico-crt/boletim_2015_versao_final.pdf</ext-link> [accessed in 09/15/2017]</citation></ref>
<ref id="ref2"><label>2.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll2">Secretaria de Vigil&#x00E2;ncia em Sa&#x00FA;de, Sa&#x00FA;de M da</collab></person-group>. Boletim Epidemiol&#x00F3;gico de HIV e Aids. (<year>2019</year>). <comment>Available from:</comment> <ext-link xlink:href="https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2019/boletim-epidemiologico-especial-hiv-aids-2019/view" ext-link-type="uri">https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2019/boletim-epidemiologico-especial-hiv-aids-2019/view</ext-link> [accessed in 11/10/2019]</citation></ref>
<ref id="ref3"><label>3.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabino</surname> <given-names>EC</given-names></name> <name><surname>Diaz</surname> <given-names>RS</given-names></name> <name><surname>Brigido</surname> <given-names>LF</given-names></name> <name><surname>Learn</surname> <given-names>GH</given-names></name> <name><surname>Mullins</surname> <given-names>JI</given-names></name> <name><surname>Reingold</surname> <given-names>AL</given-names></name> <etal/></person-group>. <article-title>Distribution of HIV-1 subtypes seen in an AIDS clinic in Sao Paulo City, Brazil</article-title>. <source>AIDS</source>. (<year>1996</year>) <volume>10</volume>:<fpage>1579</fpage>&#x2013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00002030-199611000-00018</pub-id>, PMID: <pub-id pub-id-type="pmid">8931795</pub-id></citation></ref>
<ref id="ref4"><label>4.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barreto</surname> <given-names>CC</given-names></name> <name><surname>Nishyia</surname> <given-names>A</given-names></name> <name><surname>Ara&#x00FA;jo</surname> <given-names>LV</given-names></name> <name><surname>Ferreira</surname> <given-names>JE</given-names></name> <name><surname>Busch</surname> <given-names>MP</given-names></name> <name><surname>Sabino</surname> <given-names>EC</given-names></name></person-group>. <article-title>Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil</article-title>. <source>J Acquir Immune Defic Syndr</source>. (<year>2006</year>) <volume>41</volume>:<fpage>388</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1097/01.qai.0000199097.88344.50</pub-id></citation></ref>
<ref id="ref5"><label>5.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname> <given-names>CM</given-names></name> <name><surname>Almeida</surname> <given-names>FJ</given-names></name> <name><surname>Rodrigues</surname> <given-names>R</given-names></name> <name><surname>Crozatti</surname> <given-names>M</given-names></name> <name><surname>Vazquez</surname> <given-names>CMP</given-names></name> <etal/></person-group>. <article-title>High frequency of BF mosaic genomes among HIV-1-infected children from Sao Paulo, Brazil</article-title>. <source>Arch Virol</source>. (<year>2008</year>) <volume>153</volume>:<fpage>1799</fpage>&#x2013;<lpage>806</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00705-008-0178-7</pub-id>, PMID: <pub-id pub-id-type="pmid">18716710</pub-id></citation></ref>
<ref id="ref6"><label>6.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanabani</surname> <given-names>SS</given-names></name> <name><surname>Pess&#x00F4;a</surname> <given-names>R</given-names></name> <name><surname>Soares de Oliveira</surname> <given-names>AC</given-names></name> <name><surname>Martinez</surname> <given-names>VP</given-names></name> <name><surname>Giret</surname> <given-names>MTM</given-names></name> <name><surname>de Menezes Succi</surname> <given-names>RC</given-names></name> <etal/></person-group>. <article-title>Variability of HIV-1 genomes among children and adolescents from S&#x00E3;o Paulo</article-title>. <source>Brazil PLoS One</source>. (<year>2013</year>) <volume>8</volume>:<fpage>e62552</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0062552</pub-id>, PMID: <pub-id pub-id-type="pmid">23667488</pub-id></citation></ref>
<ref id="ref7"><label>7.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonsalez</surname> <given-names>CR</given-names></name> <name><surname>Alcalde</surname> <given-names>R</given-names></name> <name><surname>Nishiya</surname> <given-names>A</given-names></name> <name><surname>Barreto</surname> <given-names>CC</given-names></name> <name><surname>Silva</surname> <given-names>FES</given-names></name> <name><surname>de Almeida</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Drug resistance among chronic HIV-1-infected patients na&#x00EF;ve for use of anti-retroviral therapy in Sao Paulo city</article-title>. <source>Virus Res</source>. (<year>2007</year>) <volume>129</volume>:<fpage>87</fpage>&#x2013;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.virusres.2007.06.021</pub-id>, PMID: <pub-id pub-id-type="pmid">17686543</pub-id></citation></ref>
<ref id="ref8"><label>8.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Br&#x00ED;gido</surname> <given-names>LFM</given-names></name> <name><surname>Ferreira</surname> <given-names>JLP</given-names></name> <name><surname>Almeida</surname> <given-names>VC</given-names></name> <name><surname>Rocha</surname> <given-names>SQ</given-names></name> <name><surname>Ragazzo</surname> <given-names>TG</given-names></name> <name><surname>Estevam</surname> <given-names>DL</given-names></name> <etal/></person-group>. <article-title>Southern Brazil HIV type 1 C expansion into the state of S&#x00E3;o Paulo, Brazil</article-title>. <source>AIDS Res Hum Retrovir</source>. (<year>2011</year>) <volume>27</volume>:<fpage>339</fpage>&#x2013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1089/aid.2010.0157</pub-id>, PMID: <pub-id pub-id-type="pmid">20950149</pub-id></citation></ref>
<ref id="ref9"><label>9.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malta</surname> <given-names>M</given-names></name> <name><surname>da Silva</surname> <given-names>CMFP</given-names></name> <name><surname>Magnanini</surname> <given-names>MM</given-names></name> <name><surname>Wirtz</surname> <given-names>AL</given-names></name> <name><surname>Periss&#x00E9;</surname> <given-names>ARS</given-names></name> <name><surname>Beyrer</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Improvement of HAART in Brazil, 1998-2008: a nationwide assessment of survival times after AIDS diagnosis among men who have sex with men</article-title>. <source>BMC Public Health</source>. (<year>2015</year>) <volume>15</volume>:<fpage>226</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12889-015-1530-y</pub-id></citation></ref>
<ref id="ref10"><label>10.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname> <given-names>MA</given-names></name> <name><surname>Aberg</surname> <given-names>JA</given-names></name> <name><surname>Hoy</surname> <given-names>JF</given-names></name> <name><surname>Telenti</surname> <given-names>A</given-names></name> <name><surname>Benson</surname> <given-names>C</given-names></name> <name><surname>Cahn</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>Antiretroviral treatment of adult HIV infection</article-title>. <source>JAMA</source>. (<year>2012</year>) <volume>308</volume>:<fpage>387</fpage>&#x2013;<lpage>402</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2012.7961</pub-id></citation></ref>
<ref id="ref11"><label>11.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sprinz</surname> <given-names>E</given-names></name> <name><surname>Netto</surname> <given-names>EM</given-names></name> <name><surname>Patelli</surname> <given-names>M</given-names></name> <name><surname>Lima</surname> <given-names>JS</given-names></name> <name><surname>Lima</surname> <given-names>MPJS</given-names></name> <name><surname>Furtado</surname> <given-names>JJD</given-names></name> <etal/></person-group>. <article-title>Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil</article-title>. <source>AIDS Res Hum Retrovir</source>. (<year>2009</year>) <volume>25</volume>:<fpage>861</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1089/aid.2009.0012</pub-id>, PMID: <pub-id pub-id-type="pmid">19689190</pub-id></citation></ref>
<ref id="ref12"><label>12.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname> <given-names>JLP</given-names></name> <name><surname>Rodrigues</surname> <given-names>R</given-names></name> <name><surname>Lan&#x00E7;a</surname> <given-names>AM</given-names></name> <name><surname>de Almeida</surname> <given-names>VC</given-names></name> <name><surname>Rocha</surname> <given-names>SQ</given-names></name> <name><surname>Ragazzo</surname> <given-names>TG</given-names></name> <etal/></person-group>. <article-title>Transmitted drug resistance among people living with HIV/aids at major cities of Sao Paulo state, Brazil</article-title>. <source>Adv Virol</source>. (<year>2013</year>) <volume>2013</volume>:<fpage>878237</fpage>:<fpage>1</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2013/878237</pub-id></citation></ref>
<ref id="ref13"><label>13.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pineda-Pe&#x00F1;a</surname> <given-names>AC</given-names></name> <name><surname>Faria</surname> <given-names>NR</given-names></name> <name><surname>Imbrechts</surname> <given-names>S</given-names></name> <name><surname>Libin</surname> <given-names>P</given-names></name> <name><surname>Abecasis</surname> <given-names>AB</given-names></name> <name><surname>Deforche</surname> <given-names>K</given-names></name> <etal/></person-group>. <article-title>Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools</article-title>. <source>Infect Genet Evol</source>. (<year>2013</year>) <volume>19</volume>:<fpage>337</fpage>&#x2013;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.meegid.2013.04.032</pub-id>, PMID: <pub-id pub-id-type="pmid">23660484</pub-id></citation></ref>
<ref id="ref14"><label>14.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Struck</surname> <given-names>D</given-names></name> <name><surname>Lawyer</surname> <given-names>G</given-names></name> <name><surname>Ternes</surname> <given-names>AM</given-names></name> <name><surname>Schmit</surname> <given-names>JC</given-names></name> <name><surname>Bercoff</surname> <given-names>DP</given-names></name></person-group>. <article-title>COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification</article-title>. <source>Nucleic Acids Res</source>. (<year>2014</year>) <volume>42</volume>:<fpage>e144</fpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gku739</pub-id>, PMID: <pub-id pub-id-type="pmid">25120265</pub-id></citation></ref>
<ref id="ref15"><label>15.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delport</surname> <given-names>W</given-names></name> <name><surname>Poon</surname> <given-names>AFY</given-names></name> <name><surname>Frost</surname> <given-names>SDW</given-names></name> <name><surname>Kosakovsky Pond</surname> <given-names>SL</given-names></name></person-group>. <article-title>Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology</article-title>. <source>Bioinformatics</source>. (<year>2010</year>) <volume>26</volume>:<fpage>2455</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btq429</pub-id>, PMID: <pub-id pub-id-type="pmid">20671151</pub-id></citation></ref>
<ref id="ref16"><label>16.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname> <given-names>AK</given-names></name> <name><surname>Zhang</surname> <given-names>M</given-names></name> <name><surname>Leitner</surname> <given-names>T</given-names></name> <name><surname>Kuiken</surname> <given-names>C</given-names></name> <name><surname>Korber</surname> <given-names>B</given-names></name> <name><surname>Morgenstern</surname> <given-names>B</given-names></name> <etal/></person-group>. <article-title>A jumping profile hidden Markov model and applications to recombination sites in HIV and HCV genomes</article-title>. <source>BMC Bioinfo</source>. (<year>2006</year>) <volume>7</volume>:<fpage>265</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2105-7-265</pub-id>, PMID: <pub-id pub-id-type="pmid">16716226</pub-id></citation></ref>
<ref id="ref17"><label>17.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Price</surname> <given-names>MN</given-names></name> <name><surname>Dehal</surname> <given-names>PS</given-names></name> <name><surname>Arkin</surname> <given-names>AP</given-names></name></person-group>. <article-title>FastTree 2--approximately maximum-likelihood trees for large alignments</article-title>. <source>PLoS One</source>. (<year>2010</year>) <volume>5</volume>:<fpage>e9490</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0009490</pub-id>, PMID: <pub-id pub-id-type="pmid">20224823</pub-id></citation></ref>
<ref id="ref18"><label>18.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stamatakis</surname> <given-names>A</given-names></name> <name><surname>Ludwig</surname> <given-names>T</given-names></name> <name><surname>Meier</surname> <given-names>H</given-names></name></person-group>. <article-title>RAxML-III: a fast program for maximum likelihood-based inference of large phylogenetic trees</article-title>. <source>Bioinformatics</source>. (<year>2005</year>) <volume>21</volume>:<fpage>456</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/bti191</pub-id>, PMID: <pub-id pub-id-type="pmid">15608047</pub-id></citation></ref>
<ref id="ref19"><label>19.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ragonnet-Cronin</surname> <given-names>M</given-names></name> <name><surname>Hodcroft</surname> <given-names>E</given-names></name> <name><surname>Hu&#x00E9;</surname> <given-names>S</given-names></name> <name><surname>Fearnhill</surname> <given-names>E</given-names></name> <name><surname>Delpech</surname> <given-names>V</given-names></name> <name><surname>Brown</surname> <given-names>AJL</given-names></name> <etal/></person-group>. <article-title>Automated analysis of phylogenetic clusters</article-title>. <source>BMC Bioinfo</source>. (<year>2013</year>) <volume>14</volume>:<fpage>317</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2105-14-317</pub-id></citation></ref>
<ref id="ref20"><label>20.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gifford</surname> <given-names>RJ</given-names></name> <name><surname>Liu</surname> <given-names>TF</given-names></name> <name><surname>Rhee</surname> <given-names>SY</given-names></name> <name><surname>Kiuchi</surname> <given-names>M</given-names></name> <name><surname>Hue</surname> <given-names>S</given-names></name> <name><surname>Pillay</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance</article-title>. <source>Bioinformatics</source>. (<year>2009</year>) <volume>25</volume>:<fpage>1197</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btp134</pub-id>, PMID: <pub-id pub-id-type="pmid">19304876</pub-id></citation></ref>
<ref id="ref21"><label>21.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Obasa</surname> <given-names>AE</given-names></name> <name><surname>Engelbrecht</surname> <given-names>S</given-names></name> <name><surname>Jacobs</surname> <given-names>GB</given-names></name></person-group>. <article-title>Near full-length HIV-1 subtype B sequences from the early south African epidemic, detecting a BD unique recombinant form (URF) from a sample in 1985</article-title>. <source>Sci Rep</source>. (<year>2019</year>) <volume>9</volume>:<fpage>6227</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-42417-1</pub-id>, PMID: <pub-id pub-id-type="pmid">30996293</pub-id></citation></ref>
<ref id="ref22"><label>22.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alencar</surname> <given-names>CS</given-names></name> <name><surname>Sabino</surname> <given-names>EC</given-names></name> <name><surname>Carvalho</surname> <given-names>SMF</given-names></name> <name><surname>Leao</surname> <given-names>SC</given-names></name> <name><surname>Carneiro-Proietti</surname> <given-names>AB</given-names></name> <name><surname>Capuani</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>HIV genotypes and primary drug resistance among HIV-seropositive blood donors in Brazil: role of infected blood donors as sentinel populations for molecular surveillance of HIV</article-title>. <source>J Acquir Immune Defic Syndr</source>. (<year>2013</year>) <volume>63</volume>:<fpage>387</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAI.0b013e31828ff979</pub-id>, PMID: <pub-id pub-id-type="pmid">23507660</pub-id></citation></ref>
<ref id="ref23"><label>23.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>V&#x00E9;ras</surname> <given-names>NMC</given-names></name> <name><surname>Gray</surname> <given-names>RR</given-names></name> <name><surname>De Br&#x00ED;gido</surname> <given-names>LFM</given-names></name> <name><surname>Rodrigues</surname> <given-names>R</given-names></name> <name><surname>Salemi</surname> <given-names>M</given-names></name></person-group>. <article-title>High-resolution phylogenetics and phylogeography of human immunodeficiency virus type 1 subtype C epidemic in South America</article-title>. <source>J Gen Virol</source>. (<year>2011</year>) <volume>92</volume>:<fpage>1698</fpage>&#x2013;<lpage>709</lpage>. doi: <pub-id pub-id-type="doi">10.1099/vir.0.028951-0</pub-id>, PMID: <pub-id pub-id-type="pmid">21450946</pub-id></citation></ref>
<ref id="ref24"><label>24.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname> <given-names>K</given-names></name> <name><surname>de Souza</surname> <given-names>L&#x00C9;</given-names></name> <name><surname>Cavalcanti</surname> <given-names>AMS</given-names></name> <name><surname>Salustiano</surname> <given-names>DM</given-names></name> <name><surname>de Medeiros</surname> <given-names>LB</given-names></name> <name><surname>da Silva</surname> <given-names>SP</given-names></name> <etal/></person-group>. <article-title>Epidemiological, clinical and antiretroviral susceptibility characterization of human immunodeficiency virus subtypes B and non-B in Pernambuco, Northeast Brazil</article-title>. <source>PLoS One</source>. (<year>2016</year>, <year>5</year>) <volume>11</volume>:<fpage>e0155854</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0155854</pub-id></citation></ref>
<ref id="ref25"><label>25.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Easterbrook</surname> <given-names>PJ</given-names></name> <name><surname>Smith</surname> <given-names>M</given-names></name> <name><surname>Mullen</surname> <given-names>J</given-names></name> <name><surname>O&#x2019;Shea</surname> <given-names>S</given-names></name> <name><surname>Chrystie</surname> <given-names>I</given-names></name> <name><surname>de Ruiter</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy</article-title>. <source>J Int AIDS Soc</source>. (<year>2010</year>) <volume>13</volume>:<fpage>4</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1758-2652-13-4</pub-id>, PMID: <pub-id pub-id-type="pmid">20205896</pub-id></citation></ref>
<ref id="ref26"><label>26.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cilliers</surname> <given-names>T</given-names></name> <name><surname>Nhlapo</surname> <given-names>J</given-names></name> <name><surname>Coetzer</surname> <given-names>M</given-names></name> <name><surname>Orlovic</surname> <given-names>D</given-names></name> <name><surname>Ketas</surname> <given-names>T</given-names></name> <name><surname>Olson</surname> <given-names>WC</given-names></name> <etal/></person-group>. <article-title>The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C</article-title>. <source>J Virol</source>. (<year>2003</year>) <volume>77</volume>:<fpage>4449</fpage>&#x2013;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.77.7.4449-4456.2003</pub-id>, PMID: <pub-id pub-id-type="pmid">12634405</pub-id></citation></ref>
<ref id="ref27"><label>27.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coetzer</surname> <given-names>M</given-names></name> <name><surname>Nedellec</surname> <given-names>R</given-names></name> <name><surname>Cilliers</surname> <given-names>T</given-names></name> <name><surname>Meyers</surname> <given-names>T</given-names></name> <name><surname>Morris</surname> <given-names>L</given-names></name> <name><surname>Mosier</surname> <given-names>DE</given-names></name></person-group>. <article-title>Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C</article-title>. <source>J Acquir Immune Defic Syndr</source>. (<year>2011</year>) <volume>56</volume>:<fpage>9</fpage>&#x2013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAI.0b013e3181f63906</pub-id>, PMID: <pub-id pub-id-type="pmid">20921899</pub-id></citation></ref>
<ref id="ref28"><label>28.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname> <given-names>TCNF</given-names></name> <name><surname>Campos</surname> <given-names>DP</given-names></name> <name><surname>Coelho</surname> <given-names>AB</given-names></name> <name><surname>Teixeira</surname> <given-names>SLM</given-names></name> <name><surname>Veloso</surname> <given-names>V</given-names></name> <name><surname>Morgado</surname> <given-names>MG</given-names></name> <etal/></person-group>. <article-title>Impact of HIV-1 subtypes on AIDS progression in a Brazilian cohort</article-title>. <source>AIDS Res Hum Retrovir</source>. (<year>2016</year>) <volume>33</volume>:<fpage>41</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1089/aid.2016.0126</pub-id></citation></ref>
<ref id="ref29"><label>29.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inocencio</surname> <given-names>LA</given-names></name> <name><surname>Pereira</surname> <given-names>AA</given-names></name> <name><surname>Sucupira</surname> <given-names>MCA</given-names></name> <name><surname>Fernandez</surname> <given-names>JCC</given-names></name> <name><surname>Jorge</surname> <given-names>CP</given-names></name> <name><surname>Souza</surname> <given-names>DF</given-names></name> <etal/></person-group>. <article-title>Brazilian network for HIV drug resistance surveillance: a survey of individuals recently diagnosed with HIV</article-title>. <source>J Int AIDS Soc</source>. (<year>2009</year>) <volume>12</volume>:<fpage>20</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1758-2652-12-20</pub-id>, PMID: <pub-id pub-id-type="pmid">19765271</pub-id></citation></ref>
<ref id="ref30"><label>30.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanabani</surname> <given-names>SS</given-names></name> <name><surname>De Pastena &#x00C9;r</surname> <given-names>S</given-names></name> <name><surname>Da Costa</surname> <given-names>AC</given-names></name> <name><surname>Martinez</surname> <given-names>VP</given-names></name> <name><surname>Kleine-Neto</surname> <given-names>W</given-names></name> <name><surname>ACS</surname> <given-names>DO</given-names></name> <etal/></person-group>. <article-title>Characterization of partial and near full-length genomes of HIV-1 strains sampled from recently infected individuals in S&#x00E3;o Paulo</article-title>. <source>Brazil PLoS One</source>. (<year>2011</year>) <volume>6</volume>:<fpage>e25869</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0025869</pub-id>, PMID: <pub-id pub-id-type="pmid">22022460</pub-id></citation></ref>
<ref id="ref31"><label>31.</label> <citation citation-type="other"><person-group person-group-type="author"><name><surname>De Guimar&#x00E3;es</surname> <given-names>PMS</given-names></name> <name><surname>Ferreira</surname> <given-names>P</given-names></name> <name><surname>LPO</surname> <given-names>C</given-names></name> <name><surname>De Cavalcanti</surname> <given-names>S</given-names></name> <name><surname>Gisl</surname> <given-names>L</given-names></name> <name><surname>Matsuda</surname> <given-names>EM</given-names></name> <etal/></person-group>. <article-title>Transmitted drug resistance among recently diagnosed adults and children in S&#x00E3;o Paulo, Brazil. AIDS res hum retroviruses</article-title> (<year>2015</year>) <volume>31</volume>:<fpage>1219</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1089/AID.2014.0354</pub-id></citation></ref>
<ref id="ref32"><label>32.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Medeiros</surname> <given-names>RM</given-names></name> <name><surname>Junqueira</surname> <given-names>DM</given-names></name> <name><surname>Matte</surname> <given-names>MCC</given-names></name> <name><surname>Barcellos</surname> <given-names>NT</given-names></name> <name><surname>Chies</surname> <given-names>JAB</given-names></name> <name><surname>Matos Almeida</surname> <given-names>SE</given-names></name></person-group>. <article-title>Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-na&#x00EF;ve population from southernmost Brazil: analysis of primary resistance mutations</article-title>. <source>J Med Virol</source>. (<year>2011</year>) <volume>83</volume>:<fpage>1682</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jmv.22188</pub-id>, PMID: <pub-id pub-id-type="pmid">21837783</pub-id></citation></ref>
<ref id="ref33"><label>33.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baral</surname> <given-names>S</given-names></name> <name><surname>Sifakis</surname> <given-names>F</given-names></name> <name><surname>Cleghorn</surname> <given-names>F</given-names></name> <name><surname>Beyrer</surname> <given-names>C</given-names></name></person-group>. <article-title>Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: a systematic review</article-title>. <source>PLoS Med</source>. (<year>2007</year>) <volume>4</volume>:<fpage>e339</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.0040339</pub-id>, PMID: <pub-id pub-id-type="pmid">18052602</pub-id></citation></ref>
<ref id="ref34"><label>34.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magnani</surname> <given-names>R</given-names></name> <name><surname>Sabin</surname> <given-names>K</given-names></name> <name><surname>Saidel</surname> <given-names>T</given-names></name> <name><surname>Heckathorn</surname> <given-names>D</given-names></name></person-group>. <article-title>Review of sampling hard-to-reach and hidden populations for HIV surveillance</article-title>. <source>AIDS</source>. (<year>2005</year>) <volume>19</volume>:<fpage>S67</fpage>&#x2013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1097/01.aids.0000172879.20628.e1</pub-id>, PMID: <pub-id pub-id-type="pmid">15930843</pub-id></citation></ref>
<ref id="ref35"><label>35.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berm&#x00FA;dez-Aza</surname> <given-names>EH</given-names></name> <name><surname>Kerr</surname> <given-names>LRFS</given-names></name> <name><surname>Kendall</surname> <given-names>C</given-names></name> <name><surname>Pinho</surname> <given-names>AA</given-names></name> <name><surname>de Mello</surname> <given-names>MB</given-names></name> <name><surname>Mota</surname> <given-names>RS</given-names></name> <etal/></person-group>. <article-title>Antiretroviral drug resistance in a respondent-driven sample of HIV-infected men who have sex with men in Brazil</article-title>. <source>J Acquir Immune Defic Syndr</source>. (<year>2011</year>) <volume>57</volume>:<fpage>S186</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAI.0b013e31821e9c36</pub-id></citation></ref>
<ref id="ref36"><label>36.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gr&#x00E4;f</surname> <given-names>T</given-names></name> <name><surname>Bello</surname> <given-names>G</given-names></name> <name><surname>Andrade</surname> <given-names>P</given-names></name> <name><surname>Arantes</surname> <given-names>I</given-names></name> <name><surname>Pereira</surname> <given-names>JM</given-names></name> <name><surname>da Silva</surname> <given-names>ABP</given-names></name> <etal/></person-group>. <article-title>HIV-1 molecular diversity in Brazil unveiled by 10 years of sampling by the national genotyping network</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>15842</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-94542-5</pub-id>, PMID: <pub-id pub-id-type="pmid">34349153</pub-id></citation></ref>
<ref id="ref37"><label>37.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Souto</surname> <given-names>B</given-names></name> <name><surname>Triunfante</surname> <given-names>V</given-names></name> <name><surname>Santos-Pereira</surname> <given-names>A</given-names></name> <name><surname>Martins</surname> <given-names>J</given-names></name> <name><surname>Ara&#x00FA;jo</surname> <given-names>PMM</given-names></name> <name><surname>Os&#x00F3;rio</surname> <given-names>NS</given-names></name></person-group>. <article-title>Evolutionary dynamics of HIV-1 subtype C in Brazil</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>23060</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-02428-3</pub-id>, PMID: <pub-id pub-id-type="pmid">34845263</pub-id></citation></ref>
<ref id="ref38"><label>38.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname> <given-names>F</given-names></name> <name><surname>Hughes</surname> <given-names>GJ</given-names></name> <name><surname>Rambaut</surname> <given-names>A</given-names></name> <name><surname>Pozniak</surname> <given-names>A</given-names></name> <name><surname>Leigh Brown</surname> <given-names>AJ</given-names></name></person-group>. <article-title>Episodic sexual transmission of HIV revealed by molecular phylodynamics</article-title>. <source>PLoS Med</source>. (<year>2008</year>) <volume>5</volume>:<fpage>e50</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.0050050</pub-id></citation></ref>
<ref id="ref39"><label>39.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname> <given-names>GJ</given-names></name> <name><surname>Fearnhill</surname> <given-names>E</given-names></name> <name><surname>Dunn</surname> <given-names>D</given-names></name> <name><surname>Lycett</surname> <given-names>SJ</given-names></name> <name><surname>Rambaut</surname> <given-names>A</given-names></name> <name><surname>Leigh Brown</surname> <given-names>AJ</given-names></name> <etal/></person-group>. <article-title>Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom</article-title>. <source>PLoS Pathog</source>. (<year>2009</year>) <volume>5</volume>:<fpage>e1000590</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1000590</pub-id>, PMID: <pub-id pub-id-type="pmid">19779560</pub-id></citation></ref>
<ref id="ref40"><label>40.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>German</surname> <given-names>D</given-names></name> <name><surname>Sifakis</surname> <given-names>F</given-names></name> <name><surname>Maulsby</surname> <given-names>C</given-names></name> <name><surname>Towe</surname> <given-names>VL</given-names></name> <name><surname>Flynn</surname> <given-names>CP</given-names></name> <name><surname>Latkin</surname> <given-names>CA</given-names></name> <etal/></person-group>. <article-title>Persistently high prevalence and unrecognized HIV infection among men who have sex with men in Baltimore: the BESURE study</article-title>. <source>J Acquir Immune Defic Syndr</source>. (<year>2011</year>) <volume>57</volume>:<fpage>77</fpage>&#x2013;<lpage>87</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAI.0b013e318211b41e</pub-id>, PMID: <pub-id pub-id-type="pmid">21297479</pub-id></citation></ref>
<ref id="ref41"><label>41.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname> <given-names>ES</given-names></name> <name><surname>Sullivan</surname> <given-names>PS</given-names></name> <name><surname>DiNenno</surname> <given-names>EA</given-names></name> <name><surname>Salazar</surname> <given-names>LF</given-names></name> <name><surname>Sanchez</surname> <given-names>TH</given-names></name></person-group>. <article-title>Number of casual male sexual partners and associated factors among men who have sex with men: results from the national HIV behavioral surveillance system</article-title>. <source>BMC Public Health</source>. (<year>2011</year>) <volume>11</volume>:<fpage>189</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2458-11-189</pub-id>, PMID: <pub-id pub-id-type="pmid">21439069</pub-id></citation></ref>
<ref id="ref42"><label>42.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baggaley</surname> <given-names>RF</given-names></name> <name><surname>White</surname> <given-names>RG</given-names></name> <name><surname>Boily</surname> <given-names>MC</given-names></name></person-group>. <article-title>HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention</article-title>. <source>Int J Epidemiol</source>. (<year>2010</year>) <volume>39</volume>:<fpage>1048</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ije/dyq057</pub-id>, PMID: <pub-id pub-id-type="pmid">20406794</pub-id></citation></ref>
<ref id="ref43"><label>43.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drescher</surname> <given-names>SM</given-names></name> <name><surname>von Wyl</surname> <given-names>V</given-names></name> <name><surname>Yang</surname> <given-names>WL</given-names></name> <name><surname>B&#x00F6;ni</surname> <given-names>J</given-names></name> <name><surname>Yerly</surname> <given-names>S</given-names></name> <name><surname>Shah</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV cohort study</article-title>. <source>Clin Infect Dis</source>. (<year>2014</year>) <volume>58</volume>:<fpage>285</fpage>&#x2013;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/cit694</pub-id>, PMID: <pub-id pub-id-type="pmid">24145874</pub-id></citation></ref>
<ref id="ref44"><label>44.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bello</surname> <given-names>G</given-names></name> <name><surname>Eyer-Silva</surname> <given-names>WA</given-names></name> <name><surname>Couto-Fernandez</surname> <given-names>JC</given-names></name> <name><surname>Guimar&#x00E3;es</surname> <given-names>ML</given-names></name> <name><surname>Chequer-Fernandez</surname> <given-names>SL</given-names></name> <name><surname>Teixeira</surname> <given-names>SLM</given-names></name> <etal/></person-group>. <article-title>Demographic history of HIV-1 subtypes B and F in Brazil</article-title>. <source>Infect Genet Evol</source>. (<year>2007</year>) <volume>7</volume>:<fpage>263</fpage>&#x2013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.meegid.2006.11.002</pub-id></citation></ref>
<ref id="ref45"><label>45.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hemelaar</surname> <given-names>J</given-names></name> <name><surname>Gouws</surname> <given-names>E</given-names></name> <name><surname>Ghys</surname> <given-names>PD</given-names></name> <name><surname>Osmanov</surname> <given-names>S</given-names></name></person-group>. <article-title>WHO-UNAIDS network for HIV isolation and characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007</article-title>. <source>AIDS</source>. (<year>2011</year>) <volume>25</volume>:<fpage>679</fpage>&#x2013;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAD.0b013e328342ff93</pub-id></citation></ref>
<ref id="ref46"><label>46.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gr&#x00E4;f</surname> <given-names>T</given-names></name> <name><surname>Passaes</surname> <given-names>CPB</given-names></name> <name><surname>Ferreira</surname> <given-names>LGE</given-names></name> <name><surname>Grisard</surname> <given-names>EC</given-names></name> <name><surname>Morgado</surname> <given-names>MG</given-names></name> <name><surname>Bello</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title>HIV-1 genetic diversity and drug resistance among treatment na&#x00EF;ve patients from southern Brazil: an association of HIV-1 subtypes with exposure categories</article-title>. <source>J Clin Virol</source>. (<year>2011</year>) <volume>51</volume>:<fpage>186</fpage>&#x2013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcv.2011.04.011</pub-id>, PMID: <pub-id pub-id-type="pmid">21622023</pub-id></citation></ref>
</ref-list>
</back>
</article>